Substance Abuse malady

Disease Ontology: A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.⁶

MalaCards: Substance Abuse, also known as substance abuse problem, is related to antisocial personality disorder and tourette syndrome. An important gene associated with Substance Abuse is MAOA (monoamine oxidase A), and among its related pathways are Phenylalanine metabolism and Tryptophan metabolism. The compounds dopac and rotigotine have been mentioned in the context of this disorder. Affiliated tissues include brain, and related mouse phenotypes are endocrine/exocrine gland and taste/olfaction.

CDC: (Data are for the U.S.)²

Wikipedia: Substance abuse, also known as drug abuse, is a patterned use of a substance (drug) in which the user...⁴⁴ more...

Aliases & Descriptions:

substance abuse 6 8 substance abuse problem 43

Diseases related to substance abuse by text searches and GeneDecks gene sharing:

(show top 50)    (show all 377)

id	Related Disease	Score	Top Affiliating Genes
1	antisocial personality disorder	29.0	MAOA, HTR1B, DRD2, DRD4, SLC6A4
2	tourette syndrome	28.1	CNR1, BDNF, GTS, MAOA, HTR1A, HTR3A
3	personality disorder	28.0	MAOA, MAOB, HTR1B, DRD2, DRD3, DRD4
4	pathological gambling	27.9	MAOA, MAOB, DRD1, DRD2, DRD3, DRD4
5	eating disorder	27.1	CNR1, BDNF, HTR1A, HTR3A, CRH, COMT
6	adhd	25.9	CNR1, BDNF, MOBP, GTS, MAOA, MAOB
7	anxiety disorder	25.9	CNR1, BDNF, MAOA, MAOB, HTR1A, HTR3A
8	alcohol abuse	25.3	GTS, GPT, HTR1B, ALDH2, DRD2, DRD3
9	mood disorder	24.7	CNR1, BDNF, MAOA, MAOB, HTR1A, HTR1B
10	cocaine abuse	24.1	BDNF, MOBP, MAOB, HTR3A, DRD2, PLP1
11	alcoholism	23.9	CNR1, MAOA, MAOB, GPT, HTR1A, HTR1B
12	parkinson's disease	23.3	CNR1, BDNF, MAOA, MAOB, HTR1A, HTR1B
13	schizophrenia	21.6	CNR1, NAT1, BDNF, MOBP, MAOA, MAOB
14	cerebritis	20.7	CNR1, BDNF, MOBP, CD4, MAOA, MAOB
15	orthostatic hypotension	13.7	MAOA, MAOB, DBH
16	myoclonus-dystonia	13.6	DRD2, DRD3, DRD4
17	agoraphobia	13.6	MAOA, HTR1A, SLC6A2
18	opiate dependence	13.5	DRD2, DRD3, COMT
19	alcoholic pancreatitis	13.5	ALDH2, CYP2E1, ADH1B
20	cognitive disease	13.5	MAOA, MAOB, HTR1A, COMT
21	novelty seeking personality	13.5	MAOA, DRD2, DRD4, COMT, SLC6A2
22	temporal lobe epilepsy	13.4	BDNF, MAOB, HTR1A, PDYN, GABBR1
23	amnestic disorder	13.3	HTR1A, HTR3A, PDYN
24	post-traumatic stress disorder	13.3	CNR1, BDNF, MAOA, DRD2, CRH, DBH
25	secondary syphilis	13.3	CYP3A4, CYP2B6, CYP2C19
26	conduct disorder	13.2	MAOA, HTR1B, SLC6A4
27	striatonigral degeneration	13.2	DRD1, DRD2, SLC6A3
28	colorectal cancer	13.2	NAT1, ALDH2, CYP2E1, CYP2D6
29	attention deficit hyperactivity disorder	13.2	DRD4, SLC6A3
30	separation anxiety disorder	13.2	DRD4, SLC6A3
31	endogenous depression	13.2	MAOA, CRH, SLC6A4
32	gonadal disease	13.1	IGF1, CRH, POMC
33	dysautonomia	13.1	BDNF, GPT, NGF, DBH
34	cluster headache	13.1	HTR1B, HTR3A, PNOC, PRL, ADH4
35	lewy body dementia	13.1	MAOB, CYP2D6, SLC6A3, SLC18A2
36	reye syndrome	13.1	GPT, GOT1, GOT2
37	sepiapterin reductase deficiency	13.1	DRD2, SLC6A3, SLC18A2
38	bipolar disorder	13.1	BDNF, HTR1A, SLC6A4
39	crigler-najjar syndrome	13.1	GOT1, GOT2, CYP3A4, CYP2B6, CYP2C19, GGT1
40	chronic pain	13.1	PNOC, COMT, NGF, PDYN, DBH
41	hepatic encephalopathy	13.1	MAOA, MAOB, GPT, DRD2, SLC17A5
42	pituitary-dependent cushing's disease	13.0	CRH, PRL, POMC
43	isolated acth deficiency	13.0	CRH, PRL, POMC
44	nelson syndrome	13.0	CRH, PRL, POMC
45	scrub typhus	13.0	GPT, OTP, SLC17A5
46	major affective disorder	13.0	HTR3A, DRD2, SLC6A4
47	antley-bixler syndrome	13.0	CYP3A4, CYP2B6, CYP2C19, POMC
48	neurogenic diabetes insipidus	13.0	CRH, PRL, POMC
49	obstructive jaundice	13.0	GPT, SLC17A5, GGT1
50	gastroparesis	13.0	HTR3A, DRD2, CYP2D6, PRL

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to substance abuse:

²²

MGI Mouse Phenotypes related to substance abuse:

²⁵

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	9.9	GGT1, DBH, OTP, DRD5, HTR1B
2	taste/olfaction phenotype	MP:0005394	9.6	CNR1, BDNF, DRD2, SLC6A3, SLC18A2
3	vision/eye phenotype	MP:0005391	8.1	TDO2, DBH, SLC17A5, SLC18A2, GGT1, NGF
4	adipose tissue phenotype	MP:0005375	8.1	GABBR1, SLC32A1, POMC, PDYN, DRD3, DRD2
5	growth/size phenotype	MP:0005378	7.2	SLC6A2, DBH, ABCB7, PDYN, SLC6A3, SLC32A1
6	integument phenotype	MP:0010771	5.5	OPRL1, PRL, DBH, TDO2, POMC, SLC6A2
7	mortality/aging	MP:0010768	5.0	POMC, DBH, TF, ABCB7, NGF, SLC6A3
8	nervous system phenotype	MP:0003631	4.4	CNR1, DRD5, OTP, CRH, PLP1, COMT
9	behavior/neurological phenotype	MP:0005386	4.1	CNR1, BDNF, MOBP, MAOA, MAOB, IGFBP3
10	homeostasis/metabolism phenotype	MP:0005376	3.1	PLP1, SLC6A4, SLC18A2, GABBR1, GGT1, SLC17A5

Articles related to substance abuse:

(show all 35)

id	Title	Authors	Year	Affiliating Genes
1	The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study. (18520596)	Kobylecki C.J.... Werge T.	2008	CYP2D6, CYP2C19
2	Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl )piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as no vel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. (17672446)	Grundt P.... Newman A.H.	2007	DRD3
3	Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment. (16824691)	Tsai S.J.	2007	BDNF
4	Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? (17291372)	Sokolov B.P.	2007	TF, PLP1, MOBP
5	Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. (16540246)	Jockers-ScherA1bl M.C.... Hellweg R.	2006	NGF
6	Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. (16109452)	Cheng C.Y.... Tsai S.J.	2005	BDNF
7	A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse (15745703)	Maitre M.... Andriamampandry C.	2005	GABBR1, SLC32A1
8	Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. (15666411)	Liu Q.R.... Uhl G.R.	2005	BDNF, BDNF-AS
9	Addiction severity assessment tool: development of a self-report measure for clients in substance abuse treatment. (15994028)	Butler S.F.... Morey L.C.	2005	ABCB7
10	Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. (15545018)	Palomo T.... Archer T.	2004	SLC6A3
11	Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. (15500971)	Jockers-ScherA1bl M.C.... Hellweg R.	2004	BDNF
12	Recognition of alcohol and substance abuse. (12722853)	Mersy D.J.	2003	GGT1
13	Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. (12496953)	Huang Y.Y.... Mann J.J.	2003	HTR1B
14	Differential associations of sex and D2 dopamine receptor (DRD2) genotype with negative affect and other substance abuse risk markers in children of alcoholics. (13679114)	Berman S.M.... Ritchie T.	2003	DRD2
15	Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene. (11054777)	Vandenbergh D.J.... Uhl G.R.	2000	COMT, DRD3, DRD4
16	Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. (11256582)	Weizman A.... Weizman R.	2000	SLC6A4
17	Association of the N-acetyltransferase I gene (NATI) with mild and severe substance abuse. (10817597)	Comings D.E.... MacMurray J.	2000	NAT1
18	Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. (10402503)	Comings D.E.... MacMurray J.P.	1999	DRD4
19	Acute pseudohepatitis in a chronic substance abuser secondary to occult seat belt injury. (10203436)	Lam E.C.... Yoshida E.M.	1999	GPT, SLC17A5
20	An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study. (9583233)	Vanyukov M.M.... Tarter R.E.	1998	DRD5
21	Growth hormone induced increase in serum IGFBP-3 level is reversed by anabolic steroids in substance abusing power athletes. (9876343)	Karila T.... Seppala T.	1998	IGF1, IGFBP3
22	A functionally deficient DRD2 variant [Ser311Cys] is not linked to alcoholism and substance abuse. (9650635)	Goldman D.... Long J.C.	1998	DRD2
23	Dopamine D3 receptor gene variants and substance abuse in schizophrenia. (9702743)	Krebs M.O.... Poirier M.F.	1998	DRD3
24	Pharmacotherapy of schizophrenia patients with comorbid substance abuse. (9165632)	Wilkins J.N.	1997	HTR1A
25	Linkage and association of a functional DRD2 variant [Ser311Cys] and DRD2 markers to alcoholism, substance abuse and schizophrenia in Southwestern American Indians. (9259374)	Goldman D.... Long J.C.	1997	DRD2
26	Exon and intron variants in the human tryptophan 2,3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders. (8873217)	Comings D.E.... MacMurray J.P.	1996	TDO2
27	Homovanillic acid and dopamine-beta-hydroxylase in male youth: relationships with paternal substance abuse and antisocial behavior. (7484985)	Gabel S.... Shindledecker R.	1995	DBH
28	Dopamine D2 receptor gene (DRD2) haplotypes and the defense style questionnaire in substance abuse, Tourette syndrome, and controls. (7647164)	Comings D.E.... Muhleman D.	1995	DRD2
29	Preliminary evidence for an association of a dinucleotide repeat polymorphism at the MAOA gene with early onset alcoholism/substance abuse. (7485245)	Vanyukov M.M.... Deka R.	1995	MAOA
30	Genetic factors in substance abuse based on studies of Tourette syndrome and ADHD probands and relatives. I. Drug abuse. (8082550)	Comings D.E.	1994	DRD2
31	Genetic factors in substance abuse based on studies of Tourette syndrome and ADHD probands and relatives. II. Alcohol abuse. (8082551)	Comings D.E.	1994	GTS
32	Comorbid psychopathy is not associated with increased D2 dopamine receptor TaqI A or B gene marker frequencies in incarcerated substance abusers. (8104042)	Smith S.S.... Newlin D.B.	1993	DRD2
33	Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. (7831443)	Hagan R.M.... Tyers M.B.	1993	HTR3A
34	Substance abuse vulnerability and D2 receptor genes. (7681236)	Uhl G.... Smith S.	1993	DRD2
35	Serotonergic responsivity and behavioral dimensions i n antisocial personality disorder with substance abuse. (2397249)	Moss H.B.... Panzak G.L.	1990	PRL

Genes related to substance abuse according to GeneCards:

(show top 50)    (show all 57)

id	Symbol	Description	Score	GeneCards Section Context
1	MAOA	monoamine oxidase A	11.1	Publications, Summaries
2	MAOB	monoamine oxidase B	11.1	Summaries
3	SLC6A2	solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2	11.1	Summaries
4	GTS	Gilles de la Tourette syndrome	11.0	Publications
5	OTP	orthopedia homeobox	11.0
6	SLC32A1	solute carrier family 32 (GABA vesicular transporter), member 1	11.0	Publications
7	TDO2	tryptophan 2,3-dioxygenase	11.0	Publications
8	GGT2	gamma-glutamyltransferase 2	11.0
9	MAMSTR	MEF2 activating motif and SAP domain containing transcriptional regulator	11.0
10	ADH4	alcohol dehydrogenase 4 (class II), pi polypeptide	11.0
11	SPG21	spastic paraplegia 21 (autosomal recessive, Mast syndrome)	11.0
12	DRD5	dopamine receptor D5	11.0	Publications
13	MOBP	myelin-associated oligodendrocyte basic protein	11.0	Publications
14	GOT2	glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2)	11.0
15	GOT1	glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)	11.0
16	GABBR1	gamma-aminobutyric acid (GABA) B receptor, 1	11.0	Publications
17	HTR1B	5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled	11.0	Publications
18	KIDINS220	kinase D-interacting substrate, 220kDa	11.0
19	DRD3	dopamine receptor D3	11.0	Publications
20	PNOC	prepronociceptin	11.0
21	PLP1	proteolipid protein 1	11.0	Publications
22	OPRL1	opiate receptor-like 1	11.0
23	ABCB7	ATP-binding cassette, sub-family B (MDR/TAP), member 7	11.0	Publications
24	NAT1	N-acetyltransferase 1 (arylamine N-acetyltransferase)	11.0	Publications
25	HTR7	5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled	11.0
26	DRD1	dopamine receptor D1	11.0
27	SLC18A2	solute carrier family 18 (vesicular monoamine), member 2	11.0
28	PDYN	prodynorphin	11.0
29	DRD4	dopamine receptor D4	11.0	Publications
30	DBH	dopamine beta-hydroxylase (dopamine beta-monooxygenase)	11.0	Publications
31	DRD2	dopamine receptor D2	11.0	Publications
32	ADH1B	alcohol dehydrogenase 1B (class I), beta polypeptide	11.0
33	BDNF	brain-derived neurotrophic factor	11.0	Publications
34	CRH	corticotropin releasing hormone	11.0
35	ALDH2	aldehyde dehydrogenase 2 family (mitochondrial)	11.0
36	CYP2E1	cytochrome P450, family 2, subfamily E, polypeptide 1	11.0
37	CYP2D6	cytochrome P450, family 2, subfamily D, polypeptide 6	11.0	Publications
38	CNR1	cannabinoid receptor 1 (brain)	11.0
39	CYP2C19	cytochrome P450, family 2, subfamily C, polypeptide 19	11.0	Publications
40	CYP2B6	cytochrome P450, family 2, subfamily B, polypeptide 6	11.0
41	HTR1A	5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled	11.0	Publications
42	HTR3A	5-hydroxytryptamine (serotonin) receptor 3A, ionotropic	11.0	Publications
43	GGT1	gamma-glutamyltransferase 1	11.0	Publications
44	CD4	CD4 molecule	11.0
45	GPT	glutamic-pyruvate transaminase (alanine aminotransferase)	11.0	Publications
46	SLC6A3	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	11.0	Publications
47	COMT	catechol-O-methyltransferase	11.0	Publications
48	SLC6A4	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	11.0	Publications
49	TF	transferrin	11.0	Publications
50	SLC17A5	solute carrier family 17 (anion/sugar transporter), member 5	11.0	Publications

Pathways related to substance abuse according to GeneDecks:

(show all 48)

id	Pathway	Score	Top Affiliating Genes
1	Phenylalanine metabolism20	10.6	GOT2, GOT1, MAOB, MAOA
2	Tryptophan metabolism20	10.4	TDO2, ALDH2, MAOB, MAOA
3	Arginine and proline metabolism20	10.4	ALDH2, GOT2, GOT1, MAOB, MAOA
4	Development Ligand-independent activation of ESR1 and ESR210	10.3	HTR7, DRD1, DRD5
5	Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics34	10.2	DRD1, DRD2, DRD3, DRD4, SLC18A2
6	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics34	10.2	SLC18A2, SLC6A4, HTR1A, MAOA
7	Tyrosine metabolism p.1 (dopamine)41	10.2	ADH1B, DBH, COMT, MAOB, MAOA
8	Tyrosine metabolism p.1 (dopamine)10	10.2	ADH1B, DBH, COMT, MAOB, MAOA
9	Cyclophosphamide Pathway, Pharmacodynamics34	10.2	ADH4, ADH1B, ALDH2
10	Celecoxib Pathway, Pharmacokinetics34	10.1	CYP3A4, CYP2D6, ADH1B
11	Imipramine/Desipramine Pathway, Pharmacokinetics34	10.1	CYP2D6, CYP2C19, CYP3A4
12	Clomipramine Pathway, Pharmacokinetics34	10.1	CYP2D6, CYP2C19, CYP3A4
13	Metabolism of amino acids and derivatives38	10.1	DBH, TDO2, GOT2, GOT1, GPT
14	Nevirapine Pathway, Pharmacokinetics34	10.1	CYP3A4, CYP2B6, CYP2D6
15	Gefitinib Pathway, Pharmacokinetics34	10.1	CYP3A4, CYP2C19, CYP2D6
16	Tramadol Pharmacokinetics34	10.1	CYP2D6, CYP2B6, CYP3A4
17	Cyclophosphamide Pathway, Pharmacokinetics34	10.0	CYP2C19, CYP2B6, CYP3A4
18	Benzodiazepine Pathway, Pharmacokinetics34	10.0	CYP2D6, CYP2C19, CYP3A4
19	Imatinib Pathway, Pharmacokinetics/Pharmacodynamics34	10.0	CYP2D6, CYP2C19, CYP3A4
20	Clopidogrel Pathway, Pharmacokinetics34	10.0	CYP2C19, CYP2B6, CYP3A4
21	CDK5 Pathway36	10.0	DRD5, DRD4, DRD3, DRD2, DRD1, BDNF
22	Tyrosine metabolism20	10.0	ADH4, ADH1B, DBH, COMT, GOT2, GOT1
23	Fluvastatin Pathway, Pharmacokinetics34	10.0	CYP3A4, CYP2C19, CYP2D6
24	Carbamazepine Pathway, Pharmacokinetics34	9.9	CYP3A4, CYP2B6, CYP2C19, CYP2E1
25	Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics34	9.9	CYP2D6, CYP2C19, CYP3A4
26	Acetaminophen metabolism41	9.9	CYP2D6, CYP2E1, CYP3A4
27	Tamoxifen Pathway, Pharmacokinetics34	9.9	CYP2D6, CYP2C19, CYP2B6, CYP3A4
28	Amine ligand-binding receptors38	9.9	HTR1A, DRD5, DRD4, DRD3, DRD2, DRD1
29	Acetaminophen metabolism10	9.9	CYP2D6, CYP2E1, CYP3A4
30	Estrone metabolism41	9.9	COMT, CYP2C19, CYP3A4
31	Citalopram Pathway, Pharmacokinetics34	9.8	SLC6A4, CYP2D6, CYP2C19, CYP3A4
32	Estrone metabolism10	9.8	COMT, CYP2C19, CYP3A4
33	Fluoxetine Pathway, Pharmacokinetics34	9.8	SLC6A4, CYP2D6, CYP2C19, CYP3A4
34	Retinol metabolism20	9.8	ADH4, ADH1B, CYP2C19, CYP2B6, CYP3A4
35	Estradiol metabolism41	9.8	COMT, CYP2D6, CYP2C19, CYP3A4
36	Estradiol metabolism10	9.8	COMT, CYP2D6, CYP2C19, CYP3A4
37	Biological oxidations38	9.7	ADH4, ADH1B, CYP2D6, CYP2C19, CYP2B6, CYP3A4
38	Statin Pathway - Generalized, Pharmacokinetics34	9.7	CYP3A4, CYP2C19, CYP2D6
39	Metabolism of xenobiotics by cytochrome P45020	9.7	ADH4, ADH1B, CYP2E1, CYP2C19, CYP2B6, CYP3A4
40	Development_Ligand-independent activation of ESR1 and ESR241	9.7	IGF1, HTR7, DRD1, DRD5
41	Selected targets of CREB110	9.7	GABBR1, PDYN, CRH, PNOC
42	Retinol metabolism10	9.6	CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4, ALDH2
43	Retinol metabolism41	9.6	CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4, ALDH2
44	Arachidonic acid metabolism20	9.6	GGT1, CYP2E1, CYP2C19, CYP2B6
45	Phenytoin Pathway, Pharmacokinetics34	9.5	COMT, CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4
46	Drug metabolism - cytochrome P45020	9.5	ADH4, ADH1B, CYP2D6, CYP2E1, CYP2C19, CYP2B6
47	Neuroactive ligand-receptor interaction20	8.7	GABBR1, OPRL1, PRL, DRD5, DRD4, DRD3
48	Metabolic pathways20	8.2	CYP2E1, COMT, TDO2, DBH, ADH1B, ADH4

Compounds related to substance abuse according to GeneDecks:

(show top 50)    (show all 555)

id	Compound	Score	Top Affiliating Genes
1	dopac32	9.9	GABBR1, DBH, COMT, DRD3, DRD1, MAOB
2	rotigotine32 9 9	11.5	CYP2D6, CYP3A4, DRD5, DRD4, DRD3, DRD2
3	ketanserin32	9.5	SLC18A2, SLC6A4, DRD2, DRD1, HTR3A, HTR1B
4	mianserin32 9 9	11.3	SLC6A4, SLC6A2, CYP2D6, CYP2B6, CYP3A4, HTR3A
5	ropinirole32 9 9	11.1	DRD2, DRD1, HTR1B, HTR1A, MAOB, DRD3
6	methylphenidate32 9 9	11.1	DRD4, DRD2, DRD1, MAOB, MAOA, DRD5
7	amine32	9.0	SLC18A2, SLC6A4, SLC6A2, DBH, COMT, CYP2D6
8	escitalopram32 34 9 18 9	13.0	BDNF, HTR1A, CYP3A4, SLC18A2, SLC6A4, SLC6A3
9	nicotine32 34 9 9	11.9	SLC17A5, SLC6A2, PDYN, CRH, CYP2D6, CYP2E1
10	homovanillic acid32 18	9.9	CRH, MAOB, MAOA, BDNF, COMT, DBH
11	choline32 9 18 9	11.9	MAOB, GPT, IGFBP3, GGT1, ADH1B, TF
12	methamphetamine32 9 9	10.8	DRD1, MAOB, MAOA, BDNF, DRD2, DRD3
13	mhpg32	8.7	COMT, CRH, DRD4, MAOB, MAOA, BDNF
14	mptp32	8.7	SLC6A3, SLC6A2, DBH, NGF, COMT, DRD3
15	lisuride32 9 9	10.6	DRD4, DRD3, DRD2, DRD1, HTR1B, HTR1A
16	perphenazine32 34 9 9	11.6	CYP2B6, CYP3A4, DRD2, DRD1, HTR3A, CYP2C19
17	paliperidone32 9 9	10.6	CYP2C19, CYP3A4, DRD4, DRD3, DRD2, DRD1
18	selegiline32 9 9	10.6	CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4, MAOB
19	venlafaxine32 34 9 18 9	12.5	SLC18A2, SLC6A4, SLC6A3, SLC6A2, CYP2D6, CYP2C19
20	amitriptyline32 34 42 9 9	12.5	SLC6A2, MAOA, CYP2D6, CYP2E1, CYP2C19, CYP2B6
21	haloperidol32 34 9 9	11.5	DRD3, DRD1, HTR3A, HTR1A, GPT, MAOB
22	bromocriptine32 9 9	10.5	CYP3A4, DRD5, DRD3, HTR7, HTR1A, POMC
23	catecholamine32	8.4	GABBR1, SLC18A2, SLC6A2, POMC, DBH, PDYN
24	chlorpromazine32 9 9	10.4	BDNF, HTR1A, HTR3A, PRL, ABCB7, CYP2D6
25	pramipexole32 9 9	10.4	HTR1A, BDNF, HTR1B, SLC18A2, SLC6A3, PRL
26	pergolide32 9 9	10.3	PRL, COMT, CYP2D6, CYP3A4, DRD5, DRD4
27	heroin32 9 9	10.2	CNR1, DRD2, DRD3, SLC6A4, SLC17A5, SLC6A3
28	ziprasidone32 9 9	10.2	HTR7, HTR3A, HTR1B, HTR1A, DRD1, DRD2
29	trimipramine32 34 9 9	11.2	SLC6A4, HTR1A, SLC6A3, SLC6A2, PRL, CYP2D6
30	desipramine32 34 9 9	11.1	SLC6A4, SLC6A3, SLC6A2, NGF, CRH, CYP2D6
31	amphetamine32 9 9	10.1	SLC18A2, MAOA, CNR1, MAOB, DRD1, DRD2
32	apomorphine32 9 9	10.0	DRD3, DRD2, DRD1, HTR1B, HTR1A, MAOB
33	quetiapine32 9 18 9	10.7	SLC6A3, PRL, CYP2D6, CYP2C19, CYP3A4, DRD5
34	paroxetine32 34 9 9	10.7	HTR3A, HTR1B, HTR1A, MAOA, DRD4, CYP2B6
35	levodopa32 9 9	9.7	SLC18A2, SLC6A3, PRL, DBH, PDYN, COMT
36	nmda32 42	8.6	PDYN, NGF, COMT, PNOC, DRD3, DRD2
37	morphine32 9 9	9.5	CYP2B6, CYP3A4, DRD2, DRD1, CNR1, CYP2D6
38	citalopram32 34 9 18 9	11.4	BDNF, CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4
39	cabergoline32 9 9	9.4	PRL, COMT, CYP3A4, DRD5, DRD4, DRD3
40	olanzapine32 34 9 18 9	11.1	DRD1, HTR7, HTR3A, HTR1B, HTR1A, BDNF
41	opiate32	7.1	DRD2, DRD1, POMC, OPRL1, PRL, DBH
42	ethanol32 34 9 18 9	11.0	GGT1, GABBR1, ADH4, ADH1B, SLC18A2, DRD1
43	testosterone32 9 18 9	10.0	CRH, CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4
44	gaba32 42	8.0	GABBR1, SLC18A2, SLC6A4, SLC32A1, SLC6A3, HTR3A
45	adenylate32	6.9	DBH, PDYN, NGF, CRH, PNOC, DRD4
46	dopamine32 9 18 9	9.4	DRD2, BDNF, DRD1, ALDH2, HTR7, HTR3A
47	acetylcholine32 9 18 9	9.3	SLC6A2, HTR3A, HTR1A, BDNF, CNR1, HTR7
48	5-hydroxytryptamine32	6.0	GABBR1, SLC18A2, SLC6A4, DRD2, HTR7, HTR3A
49	epinephrine32 9 18 9	8.5	SLC17A5, SLC6A2, POMC, PRL, DBH, TF
50	cocaine32 9 9	6.4	BDNF, CNR1, MOBP, GGT1, GABBR1, SLC18A2

Cellular components related to substance abuse according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	neuronal cell body	GO:043025	9.4	SLC18A2, SLC6A3, DBH, DRD4, DRD1, HTR3A
2	integral to plasma membrane	GO:005887	7.7	CNR1, GABBR1, SLC18A2, SLC6A4, SLC17A5, SLC6A3
3	plasma membrane	GO:005886	6.7	PDYN, OPRL1, SLC6A2, SLC6A3, SLC32A1, SLC6A4

Biological processes related to substance abuse according to GeneDecks:

(show top 50)    (show all 51)

id	Name	GO ID	Score	Top Affiliating Genes
1	phospholipase C-activating dopamine receptor signaling pathway	GO:060158	10.5	DRD5, DRD2, DRD1
2	adenylate cyclase-activating dopamine receptor signaling pathway	GO:007191	10.5	DRD5, DRD3, DRD1
3	response to histamine	GO:034776	10.5	DRD4, DRD3, DRD2
4	regulation of dopamine uptake involved in synaptic transmission	GO:051584	10.5	DRD3, DRD2, DRD1
5	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:007195	10.4	DRD4, DRD3, DRD2
6	regulation of dopamine secretion	GO:014059	10.4	DRD3, DRD2, HTR1B
7	G-protein coupled receptor internalization	GO:002031	10.4	DRD3, DRD2, HTR1B
8	behavioral response to ethanol	GO:048149	10.4	DBH, DRD4, DRD2
9	fear response	GO:042596	10.4	DBH, DRD4, BDNF
10	behavioral response to cocaine	GO:048148	10.4	DRD1, DRD2, DRD3, DRD4
11	negative regulation of protein secretion	GO:050709	10.4	DRD4, DRD3, DRD2
12	dopamine metabolic process	GO:042417	10.4	DRD4, DRD3, DRD2, DRD1
13	negative regulation of adenylate cyclase activity	GO:007194	10.4	GABBR1, DRD4, DRD3, DRD2
14	ethanol oxidation	GO:006069	10.3	ALDH2, ADH1B, ADH4
15	negative regulation of blood pressure	GO:045776	10.3	DRD5, DRD3, DRD2, CNR1
16	aspartate biosynthetic process	GO:006532	10.3	GOT2, GOT1
17	visual learning	GO:008542	10.3	DRD1, DRD2, DRD3, DRD5, DBH
18	regulation of dopamine metabolic process	GO:042053	10.3	DRD1, DRD4, SLC6A3
19	sensitization	GO:046960	10.3	DRD1, DRD5
20	arachidonic acid secretion	GO:050482	10.2	DRD4, DRD3, DRD2
21	prepulse inhibition	GO:060134	10.2	DRD1, DRD2, DRD3, SLC6A3
22	G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:007187	10.2	DRD1, HTR7, HTR1B, CNR1
23	response to pain	GO:048265	10.2	SLC6A2, DBH, COMT
24	glutamate catabolic process to 2-oxoglutarate	GO:019551	10.2	GOT2, GOT1
25	synaptic transmission, dopaminergic	GO:001963	10.2	CRH, DRD5, DRD4, DRD3, DRD2, DRD1
26	dopamine catabolic process	GO:042420	10.2	SLC6A3, DBH, COMT, MAOA
27	monoamine transport	GO:015844	10.1	SLC18A2, SLC6A4, SLC6A3, SLC6A2
28	response to iron ion	GO:010039	10.1	SLC6A3, DBH, DRD2
29	social behavior	GO:035176	10.1	SLC6A4, DBH, DRD4, DRD3
30	cellular amino acid biosynthetic process	GO:008652	10.1	GOT2, GOT1, GPT
31	neurotransmitter biosynthetic process	GO:042136	10.1	SLC6A3, COMT, ALDH2, MAOA
32	response to amphetamine	GO:001975	10.1	SLC18A2, DBH, DRD5, DRD4, DRD3, DRD2
33	locomotory behavior	GO:007626	10.1	DRD2, DRD3, DBH, SLC6A3, SLC18A2
34	response to ethanol	GO:045471	10.0	GABBR1, SLC6A3, DRD3, HTR1B, GOT2, MAOB
35	exogenous drug catabolic process	GO:042738	10.0	CYP2C19, CYP2B6, CYP3A4
36	glutamate catabolic process to aspartate	GO:019550	10.0	GOT2, GOT1
37	heterocycle metabolic process	GO:046483	10.0	CYP2D6, CYP2E1, CYP2C19, CYP3A4
38	monoterpenoid metabolic process	GO:016098	10.0	CYP2D6, CYP2E1, CYP2C19, CYP3A4
39	response to nicotine	GO:035094	9.8	GABBR1, SLC6A3, NGF, DRD2, CNR1
40	drug metabolic process	GO:017144	9.8	CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4
41	memory	GO:007613	9.7	CNR1, DRD1, NGF, DBH, SLC6A4
42	response to cocaine	GO:042220	9.7	SLC18A2, SLC6A3, DRD5, DRD3, DRD2, HTR3A
43	steroid metabolic process	GO:008202	9.7	CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4
44	oxidation-reduction process	GO:055114	9.6	CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4
45	cellular nitrogen compound metabolic process	GO:034641	9.4	POMC, DBH, TDO2, GOT2, GOT1, GPT
46	transmembrane transport	GO:055085	9.1	SLC18A2, SLC17A5, SLC32A1, SLC6A3, SLC6A2, TF
47	response to drug	GO:042493	9.0	SLC6A4, SLC6A3, NGF, COMT, DRD3, DRD2
48	synaptic transmission	GO:007268	8.7	MAOA, GABBR1, SLC18A2, HTR1B, HTR3A, HTR7
49	xenobiotic metabolic process	GO:006805	8.6	NAT1, MAOA, MAOB, ALDH2, CYP3A4, CYP2B6
50	small molecule metabolic process	GO:044281	7.3	CYP2D6, COMT, TDO2, DBH, POMC, ADH1B

Molecular functions related to substance abuse according to GeneDecks:

(show all 16)

id	Name	GO ID	Score	Top Affiliating Genes
1	dopamine receptor activity	GO:004952	10.4	DRD5, DRD4, DRD1
2	dopamine receptor activity, coupled via Gi/Go	GO:001591	10.3	DRD4, DRD3, DRD2
3	dopamine receptor activity, coupled via Gs	GO:001588	10.2	DRD1, DRD5
4	serotonin binding	GO:051378	10.2	HTR3A, HTR1B, HTR1A, MAOA
5	serotonin receptor activity	GO:004993	10.1	HTR1A, HTR1B, HTR3A, HTR7
6	serotonin transmembrane transporter activity	GO:015222	10.0	SLC6A4, SLC18A2
7	L-aspartate:2-oxoglutarate aminotransferase activity	GO:004069	10.0	GOT1, GOT2
8	monoamine transmembrane transporter activity	GO:008504	10.0	SLC18A2, SLC6A4, SLC6A3, SLC6A2
9	dopamine binding	GO:035240	9.9	SLC6A3, DRD5, DRD4, DRD3, DRD2, DRD1
10	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavopr	GO:016712	9.8	CYP2E1, CYP2B6, CYP3A4
11	oxygen binding	GO:019825	9.7	CYP3A4, CYP2C19, CYP2E1, TDO2
12	monooxygenase activity	GO:004497	9.6	CYP3A4, CYP2B6, CYP2C19, CYP2E1, CYP2D6
13	heme binding	GO:020037	9.4	TDO2, CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4
14	electron carrier activity	GO:009055	9.3	CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4, ALDH2
15	iron ion binding	GO:005506	9.3	TDO2, CYP2D6, CYP2E1, CYP2C19, CYP2B6, CYP3A4
16	drug binding	GO:008144	9.1	CNR1, SLC18A2, SLC6A3, CYP2D6, DRD5, DRD4